The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Discover how the ALYREF biomarker predicts bladder cancer aggressiveness and boosts immunotherapy response. Find out more ...

Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.

Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure. In considering outcomes for ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

A study finds DR-70 protein levels can help detect bladder cancer early and identify invasive disease. Learn more about this promising diagnostic biomarker.

Gene Holdings ( ($ENGN) ) has issued an announcement. enGene Holdings Inc. has reported promising preliminary data from its Phase 2 LEGEND trial ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer care. From minimally invasive surgical advances to emerging drug combinations ...

According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...

Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...